Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses

PDF

Authors
  1. Hu, W.-G.
  2. Steigerwald, R.
  3. Kalla, M.
  4. Volkmann, A.
  5. Noll, D.
  6. Nagata, L.P.
Corporate Authors
Defence Research and Development Canada, Suffield Research Centre, Ralston AB (CAN);Bavarian Nordic GmbH, Fraunhoferstrasse Martinsried (GERMANY);BAVARIAN NORDIC WASHINGTON DC INC., WASHINGTON DC (USA)
Abstract
The three encephalitic alphaviruses, wester, eastern, and Venezuelan equine encephalitis viruses (WEEV, EEEV, and VEEV) are potential biothreat agents due to high infectivity through aerosol exposure, ease of production in large amounts, and relative stability in the environment. Currently, there is no licensed vaccine for human use to these three encephalitic alphaviruses, and efforts to move vaccine Ankara-Bavarian Nordic (MVA-BN®) vaccine platform was used to construct and produce three monovalent recombinant MVA-BN-based encephalitic alphavirus vaccines, MVA-BN-W + E + V, or the trivalent vaccine MVA-BN-WEV at a four-week interval. Two weeks after the booster immunization, the mice were instilled intranasally with 5 x 10-3 to 1 x 10-4 plaque forming units of WEEV, EEEV, or VEEV. All mice immunized with monovalent vaccines survived the respective virus challenge without any signs of illness or weight loss, while all the control mice died. The triple mixture of vaccines or the trivalent vaccine also provided 90 to 100% protection to the mice against WEEV and VEEV challenges, and 60% to 90% protection against EEV challenge. These data suggests that each monovalent MVA-BN-W, MVA-BN-E, and MVA-BN-V is a potential vaccine candidate against respective enciphalitic alphavirus and the three monovalent vaccines can be given in a mixture (MVA-BN-W + E + V) or the trivalent vaccine MVA-BN-WEV can serve as a true multivalent vaccine significantly reducing efficacy against WEEV and VE
Keywords
MVA-BN;Vaccines;Encephalitic alphaviruses;Monovalent;Mixture of vaccines;Trivalent;Protective efficacy
Report Number
DRDC-RDDC-2018-P108 — External Literature (P)
Date of publication
01 Aug 2018
Number of Pages
10
Reprinted from
Vaccine 36 (2018) 5194 5203 July 2018
DSTKIM No
CA046926
CANDIS No
807372
Format(s):
Electronic Document(PDF)

Permanent link

Document 1 of 1

Date modified: